IVA earnings

Daix (France), New York (United States), March 23, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva's management will hold a conference call in English, followed by a Q&A session, on Tuesday, March 31, 2026, at 8:00 am (New York), 2:00 pm (Paris). Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon regis

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.Last patient randomization is anticipated in the first half of 20

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In September 2023, Inventiva entered into an exclusive licensing agreement with Hepalys to develop and commercialize lanifibranor in Japan and South Korea In January 2024, Inventiva received the second tranche of €25 million under the EIB loan agreement following its August 2023 financing of €35.7 million in gross proceeds, the upfront payment of $10 mill

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2023 full-year financial results on Thursday, March 28, 2024. Inventiva's 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, C

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis.Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.Treatment with lanifibranor alone and in combination with empagliflozin decreased the ratio of visceral abdominal fat

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH,  and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D).   Conference Call / Webcast Details The C

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelRevenues amounted to €1.9 million for the first half of 2023In August 2023, Inventiva received a financing of approximately €35.7 million from new and existing investors consisting of €30.6 million from a capital increase and €5.1 million issuance of royalty certificatesIn September 2023, Inventiva announced an exclusive licensing agreement with Hepalys Pharma, Inc., to develop and commercialize lanifibranor for the treatment of NASH and potentially other met

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD).A significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as NAFLD resolution with lanifibranor compared to placebo.  Lanifibranor treatment significantly improved both hepatic and peripheral insulin sensitivity (i.e. fasting plasma insulin, fasting hepatic glucose production, hepatic insulin resistance index, insulin-stimulated muscle glucose disposal), which translated into better glycemic

  Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹  upfront payment Inventiva received the first tranche of €25 million under its credit facility with the European Investment Bank (EIB) Screening of the first patients in LEGEND, a Phase IIa combination trial wi

Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2022 full-year financial results on Thursday, March 30, 2023. Inventiva's 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqu

Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that AbbVie communicated during their third-quarter financial results1 on Friday October 28th, that they decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva's partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flowInventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank (EIB)2Inventiva raised approximately €14.7 million through a combination of Inventiva's At-The-Market (ATM) program (for €9.4 million in gross proceeds) and new state-backed bank financing (for €5.3 million)Screening  of the first patients in Phase IIa combination tr

Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2022 half-year financial results on Thursday, September 22, 2022. Inventiva's 2022 half-year financial results will be published on Wednesday, September 21, 2022 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of

Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's full-year financial results for 2021 on Tuesday, March 8, 2022. Inventiva's 2021 full-year financial results will be released on Monday, March 7, 2022 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific O

Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape by Prof. Nezam AfdhalUpdate on Inventiva's Phase II clinical trial evaluating lanifibranor in patients with type 2 diabetes (T2D) and non alcoholic fatty liver disease (NAFLD) by Prof. Kenneth CusiPresentation of Inventiva's Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in patients with non-cirrhotic NASH and T2D by Prof. Michelle LaiVirtual webcast event on November 19, 2021 at 10:30 am (ET) / 4:30 pm (CET) Daix (France), Long Island City (New York, United St

Daix (France), September 10, 2021 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company's first-half financial results for 2021 on Tuesday, September 21, 2021. Inventiva's 2021 first-half financial results will be released on Monday, September 20, 2021 at 4:00 pm (New York), 10:00 pm (Paris).   Frédéric Cren, Chairman, CEO and cofounder of Inventiva and Jean Volatier, C